US Energy Initiatives (PINK:USEI) reached up 52.17% in morning trading to $.028 with 3.5M shares traded. US Energy Initiatives has two separate energy initiatives; one in the automotive sector and one in the oil, gas & technology sector. They will continue to develop and market their automotive technologies which they have done since 1996; and focus on manufacturing and marketing GREEN retrofit systems for the conversion of gasoline and diesel engines, and market new and innovative hybrid fuels. They will also acquire and develop stranded or un-recovered oil properties for enhanced oil production, create partnerships with operators, create strategic alliances for primary and secondary recovery, and partner with farm-ins on properties where technology will be utilized to improve recovery efforts. Their goal here is to become an environmentally responsible oil and gas company; utilizing all methods available to improve oil recovery. US Energy Initiatives (USEI.OTC) announced Friday that the Company is making significant progress after sitting idle for years and is now positioning itself to begin the commercialization of an innovative hybrid fuel: the terms will be released in the coming weeks.
Cleveland BioLabs, Inc. (Nasdaq:CBLI) reached up 58.27% in morning trading to $2.00 with 1M shares traded. Cleveland BioLabs, Inc. is a clinical-stage biotechnology company leveraging deep mechanistic understanding of the cell death process, apoptosis, to develop a robust pipeline of compounds primarily focused on oncology applications and mitigation of radiation injury. The Company's lead compound is being developed as both a radiation countermeasure and a direct acting anticancer agent. The Company has two operating subsidiaries, Incuron, LLC, and Panacela Labs, Inc., and strategic relationships with the Cleveland Clinic, Roswell Park Cancer Institute, the Children's Cancer Institute of Australia and the Armed Forces Radiobiology Research Institute. Cleveland BioLabs, Inc. (Nasdaq:CBLI - News) today announced strong survival results for its randomized, blinded, placebo-controlled efficacy study of CBLB502 in 179 non-human primates (NHPs) conducted under Good Laboratory Practice (GLP) with elements of Good Clinical Practice (GCP), as required by the U.S. Food and Drug Administration's (FDA) Animal Rule. The study demonstrated with a high degree of statistical significance the dose-response relationship between the administration of CBLB502 and the survival of lethally irradiated animals, the study's primary endpoint.
Biopharma (Nasdaq:GALE) reached up 13.95% in morning trading to $1.47 with 3.5M shares traded. Galena Biopharma, Inc. is a Portland, Oregon-based biopharmaceutical company that develops innovative, targeted oncology treatments that address major unmet medical needs to advance cancer care. Galena Biopharma (Nasdaq:GALE - News) presented data from the Phase 1/2 clinical trial of NeuVax(TM) (E75) at the American Society of Clinical Oncology (ASCO) 2012 Annual Meeting being held June 1-5, 2012 in Chicago, Illinois. The poster entitled, "Safety and Long-Term Maintenance of Anti-HER2 Immunity Following Booster Inoculations of the E75 Breast Cancer Vaccine" (Abstract #2529) was presented on Saturday, June 2, 2012 and was selected for the oral session, "Developmental Therapeutics -- Clinical Pharmacology and Immunotherapy."
For a detailed quote on any of the following companies, or to read the full news articles visit PennyTrader.com
About PennyTrader.com
PennyTrader.com is a financial and investor relations website committed to covering the microcap market space including Pink Sheets and OTC Bulletin Board and sub-$5 big board stocks. We strive to provide you with the best stocks alerts in the market! We focus on OTCBB, OTC, penny stocks, sub-$5 big board stocks, and timely stocks picks and alerts. Our goal is to inform you of the HOTTEST stocks in the market before they move. Our staff has years experience in the stock market, and we are confident that you’ll be impressed with the results of our stock picks! If you wish to feature your organization on our website then you can contact us at publisher@pennytrader.com.
Disclosure: PennyTrader.com is not currently being compensated for any stocks covered in this midday report.
PennyTrader.com is not a registered investment advisers or broker/dealer. PennyTrader.com makes no recommendation that the purchase of securities of companies profiled in this press release is suitable or advisable for any person or that an investment such securities will be profitable. In general, given the nature of the micro cap companies covered and the potential lack of an active trading market their securities, investing in such securities is highly speculative and carries a high degree of risk. For our full disclaimer go to CLICK HERE
